No Increased Stroke Risk for Users of Typical Antipsychotics
Typical antipsychotic use is not associated with an increased risk for strokes compared with atypical antipsychotic use in a non-elderly population and patients without dementia.
Psychosis
Cannabis-Induced Psychosis in Teenagers and Young Adults: Risk Factors, Detection, Management
An increasing number of adolescents and young adults use cannabis for recreational or medicinal purposes, unaware that potential adverse effects include psychosis.
Substance Use, Duration of Symptoms Predict Hospitalization in First-Episode Psychosis
A lack of belief in the value of medication and the number of previous hospitalizations also predict hospitalization in first-episode psychosis.
NYC START Connects Patients With First-Episode Psychosis to Mental Health Services
The relative success of NYC START might lead other local governments to fund similar programs to connect individuals with first-episode psychosis to available community supports.
Familial Risk Plays a Moderate Role in Substance-Induced Psychotic Disorder
Schizophrenia subsequent to substance-induced psychosis is likely a drug-precipitated disorder in highly vulnerable individuals, not a syndrome resulting from drug exposure.
Psychotic Symptoms May Worsen During Perimenstrual Phase of the Menstrual Cycle
Worsening psychotic symptoms around the time of menstruation support the estrogen protection hypothesis.
Leveraging Pharmacogenetic Testing to Improve Treatment Adherence in Mental Illness
Leveraging pharmacogenetics for selecting treatments may benefit patients with treatment-resistant schizophrenia and other psychotic disorders.
Amphetamine, Methylphenidate ADHD Treatment Linked to Adolescent Psychosis
Among adolescents and young adults with ADHD receiving prescription stimulants, new-onset psychosis occurred in approximately 1 in 660 patients.
Novel Treatment for Schizophrenia Gets FDA’s Breakthrough Therapy Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia. SEP-363856 is believed to work by activating trace amine-associated receptor 1 (TAAR1) in addition to 5-HT1A receptors; unlike other antipsychotics, this novel agent does not bind to D2 or 5-HT2A receptors. The Breakthrough Therapy designation was…
Pimavanserin and Quetiapine Comparable for Psychosis in Parkinson Disease
There were no significant differences between pimavanserin and quetiapine in time to discontinuation, mortality, or improvement in psychosis in patients with Parkinson disease and Lewy body dementia.
Next post in Parkinson Disease
